Markets

XBiotech Developing Combination Antibody Therapy For Influenza-COVID-19 Co-Infections

(RTTNews) - XBiotech Inc. (XBIT) said the company is developing a new therapy, FLUVID, for treating illness caused by combined infections with influenza and COVID-19. This therapy will combine XBiotech's influenza True Human antibodies together with its recently discovered COVID-19 antibodies into one treatment.

John Simard, XBiotech CEO, said: "We believe a combination antibody therapy is the best way to prepare for flu season or a larger influenza pandemic outbreak that may occur in combination with COVID-19. We now have candidate therapeutics to treat real-world infections which will involve multiple pathogens and co-infections."

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

XBIT

Latest Markets Videos

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More